Comparison of Effects of Serum n-3 to n-6 Polyunsaturated Fatty Acid Ratios on Coronary Atherosclerosis in Patients Treated With Pitavastatin or Pravastatin Undergoing Percutaneous Coronary Intervention
Comparison of Effects of Serum n-3 to n-6 Polyunsaturated Fatty Acid Ratios on Coronary Atherosclerosis in Patients Treated With Pitavastatin or Pravastatin Undergoing Percutaneous Coronary Intervention
复制标题
DOI：
10.1016/j.amjcard.2013.01.327
复制
发表时间：
2013-06-01
影响因子：
2.8
通讯作者：
Michishita, Ichiro
中科院分区：
文献类型：
--
作者：
Nozue, Tsuyoshi;Yamamoto, Shingo;Michishita, Ichiro
低n-3与n-6多不饱和脂肪酸（PUPA）比例与心血管事件有关。然而，这一比例对冠状动脉粥样硬化的影响尚未得到充分研究，特别是在接受不同类型他汀类药物治疗的患者中。本研究比较了n-3和n-6 PUFA比值对匹伐他汀和普伐他汀治疗患者冠状动脉粥样硬化的影响。在101例经皮冠状动脉介入治疗时和他汀类药物治疗8个月后，应用虚拟组织学血管内超声评估经皮冠状动脉介入血管非罪魁祸首病变的冠状动脉粥样硬化。匹伐他汀和普伐他汀分别治疗51例和50例患者。二十二碳六烯酸(DHA)/花生四烯酸（AA）、二十碳五烯酸+ DHA/AA比值变化与匹伐他汀组斑块体积百分比变化无相关性，而普伐他汀组斑块体积百分比变化与DHA/AA比值变化（r = -0.404, p = 0.004）、二十碳五烯酸+ DHA/AA比值变化（r = -0.350, p = 0.01）呈显著负相关。多因素回归分析显示，年龄（β = 0.306, p = 0.02）、是否患有糖尿病（β = 0.250, p = 0.048）和DHA/AA比值变化（β = -0.423, p = 0.001）是斑块体积百分比变化的显著预测因子。用普伐他汀治疗的患者。总之，在普伐他汀治疗期间，n-3和n-6 PUPA比值的降低与冠状动脉粥样硬化的进展有关，而在匹伐他汀治疗期间则无关。(C) 2013爱思唯尔公司版权所有。
A low n-3 to n-6 polyunsaturated fatty acid (PUPA) ratio is associated with cardiovascular events. However, the effects of this ratio on coronary atherosclerosis have not been fully examined, particularly in patients treated with different types of statins. This study compared the effects of n-3 to n-6 PUFA ratios on coronary atherosclerosis in patients treated with pitavastatin and pravastatin. Coronary atherosclerosis in nonculprit lesions in the percutaneous coronary intervention vessel was evaluated using virtual histology intravascular ultrasound in 101 patients at the time of percutaneous coronary intervention and 8 months after statin therapy. Pitavastatin and pravastatin were used to treat 51 and 50 patients, respectively. Changes in the docosahexaenoic acid (DHA)/arachidonic acid (AA) and eicosapentaenoic acid + DHA/AA ratios were not correlated with the percentage change in plaque volume in the pitavastatin group, whereas the percentage change in plaque volume and the changes in the DHA/AA ratio (r = -0.404, p = 0.004) and eicosapentaenoic acid + DHA/AA ratio (r = -0.350, p = 0.01) in the pravastatin group showed significant negative correlations. Multivariate regression analysis showed that age (beta = 0.306, p = 0.02), the presence of diabetes mellitus (beta = 0.250, p = 0.048), and changes in the DHA/AA ratio (beta = -0.423, p = 0.001) were significant predictors of the percentage change in plaque volume in. patients treated with pravastatin. In conclusion, decreases in n-3 to n-6 PUPA ratios are associated with progression in coronary atherosclerosis during pravastatin therapy but not during pitavastatin therapy. (C) 2013 Elsevier Inc. All rights reserved.